A clinical observational study on the application of enhanced recovery after laparoscopic pancreaticoduodenectomy

Rui Liao1*, Jun-Cai Li2†, Jie Chen3, Xu-Fu Wei1 and Xiong Yan1*  
1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, 2Department of Thoracic Surgery, The People’s Hospital of Yubei District of Chongqing City, Chongqing, China, 3Department of Hepatobiliary Surgery, Zigong Fourth People’s Hospital, Zigong, China  

Purpose: The safety and feasibility of enhanced recovery after surgery (ERAS) for laparoscopic pancreaticoduodenectomy (LPD) are unclear. The aim of this retrospective clinical study was to evaluate the impact of ERAS protocols for LPD.  

Patients and methods: Between March 2016 and December 2018, a total of 34 consecutive patients with ERAS for LPD were prospectively enrolled and compared with 68 consecutive patients previously treated for non-ERAS after LPD during an equal time frame. The intraoperative and postoperative data were collected and comparatively analyzed.  

Results: The mean length of postoperative hospital stay (15.8 ± 3.4 and 23.1 ± 5.1 days, P < 0.001) was reduced significantly in ER group than those in non-ER group. The operation time (462.7 ± 117.0 vs. 450.9 ± 109.8 min, P = 0.627) and intraoperative blood loss (523.5 ± 270.0 vs. 537.5 ± 241.8 ml, P = 0.800) were similar in the two groups. The complications (ER: 32.4% vs. non-ER: 35.3%, P > 0.05) and their severities (Clavien–Dindo grade ≥3 complications, 2 vs. 5 patients; P = 0.783) of patients with ERAS protocols were not increased. No difference in mortality and readmission rates was found. Finally, the total medical costs ($2.1 ± 0.7 × 104 and $2.3 ± 0.7 × 104, P = 0.017) in ER group were lower than those in non-ER group.  

Conclusion: the ERAS is safe and effective in the perioperative period of LPD. It could effectively reduce the length of postoperative stay and medical costs, and does not increase the incidence of postoperative complications.  

KEYWORDS  
laparoscopic, pancreaticoduodenectomy, enhanced recovery after surgery, postoperative outcome, complication  

Introduction  

Enhanced recovery after surgery (ERAS) protocols are referred to as “fast-track surgery”, which are multimodal, evidence-based approaches to the perioperative management of patients undergoing different types of operations that are designed to reduce the surgical stress response and accelerate recovery (1). The main principle of ERAS protocols is to reduce intraoperative stress and prevent immunosuppression. Moreover, ERAS protocols aim to decrease the incidence of postoperative
complications and the length of hospital stays, which in turn reduce hospitalization costs. Additionally, preventing both tumour seeding and recurrence are included in the components of ERAS protocols (2). In recent years, similar promising studies have been gradually reported for various types of surgery with important clinical benefits, especially in colorectal surgery (3, 4).

With the increased publication of ERAS guidelines to optimize patient outcomes after more complex and high-risk surgical procedures, there is growing enthusiasm and interest among healthcare professionals for studies on ERAS programmes in patients after open pancreateoduodenectomy (OPD) (5, 6). Encouragingly, most initial studies have shown the feasibility and safety of ERAS for OPD, such as early discharge (6), decreased morbidity (7), and fewer postoperative complications (8). However, laparoscopic PD (LPD) remains a challenging procedure due to its technical limitations and the need for advanced skills in laparoscopy. Of note, LPD is not recommended as a preferred surgical approach if the surgeon has not mastered the long learning curve according to some clinical observations because of higher morbidity, more severe pancreatic fistulae and post-pancreatectomy haemorrhage (9). To date, few studies have been performed regarding ERAS programmes for LPD.

In the present retrospective observational study, we primarily aimed to investigate the effect of ERAS protocols in patients after LPD, including length of postoperative hospital stay and medical costs. The secondary aims were to assess the postoperative recovery and outcomes of LPD in patients in an academic medical centre in China.

Materials and methods

Study population

This is a retrospective clinical study on a collected data base. Between March 2016 and December 2018, a total of 102 patients who underwent LPD were enrolled in this study according to the inclusion criteria: (1) tumors of pancreas, duodenum and lower bile duct; (2) biliary obstruction caused by benign tumors (3) all patients had complete laboratory test data; (4) no anticancer treatments before the operation; (5) curative resection of all tumor nodules; and (6) complete patient records and follow-up data. Patients who had tumour metastasis and other organ resection were not considered eligible for this study. These surgeries were performed by Dr. De-Wei Li and Dr. Xiong Yan, who are experienced laparoscopic surgical experts and have completed more than 50 cases of LPD. Among these cases, 34 patients were prospectively included in enhanced recovery (ERAS group). These patients were compared with 68 consecutive patients after LPD under the care of the same consultants previously receiving standard care during an equal time frame (non-ERCP group, non-ER, Table 1). The Clavien-Dindo classification was used to evaluate the postoperative complications (10). This study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration and has been reviewed and approved by the Ethics Review Board of the First Affiliated Hospital of Chongqing Medical University (2022–031). All patients and/or their legal guardians were required to provide informed consent to participate in this study.

Table 1

| Characteristics | ER group (n = 34) | Non-ER group (n = 68) | P value |
|-----------------|-----------------|----------------------|--------|
| Gender (male)   | 19 (55.9%)      | 39 (57.4%)           | 1.000  |
| Age (years)     | 59.3 ± 9.5      | 61.1 ± 9.1           | 0.374  |
| BMI (kg/m²)     | 22.3 ± 1.8      | 22.9 ± 1.9           | 0.174  |
| Abdominal surgery history (year) | 10 (29.4%) | 17 (25.0%) | 0.641 |
| Preoperative abdominal pain | 14 (41.2%) | 31 (45.6%) | 0.672 |
| Preoperative diabetes (year) | 7 (20.6%) | 12 (17.6%) | 0.719 |
| Preoperative hypertension (year) | 12 (35.3%) | 22 (32.4%) | 0.766 |
| Hemoglobin (g/L) | 122.1 ± 14.53 | 117.6 ± 15.4 | 0.149 |
| WBC (10^9/L)    | 7.6 ± 2.3       | 7.7 ± 2.4            | 0.713  |
| Neutrophil (10^9/L) | 4.4 ± 2.0 | 5.9 ± 6.2 | 0.091 |
| Albumin (g/L)   | 39.7 ± 4.4      | 40.8 ± 4.0           | 0.216  |
| TBIL (µmol/L)   | 135.4 ± 81.7    | 122.7 ± 83.1         | 0.465  |
| DBIL (µmol/L)   | 101.1 ± 77.9    | 97.9 ± 73.3          | 0.842  |
| ALT (U/L)       | 158.0 ± 130.8   | 136.1 ± 102.8        | 0.397  |
| AST (U/L)       | 140.7 ± 119.6   | 120.0 ± 99.0         | 0.388  |
| PT (s)          | 12.9 ± 1.5      | 13.0 ± 1.6           | 0.652  |
| ASA score       |                |                      | 0.337  |
| I               | 16 (47.1%)      | 36 (53.0%)           |        |
| II              | 18 (52.9%)      | 29 (42.6%)           |        |
| III             | 0 (0)           | 3 (4.4%)             |        |
| Child-Pugh Grade | 1.000          |                     |        |
| A               | 14 (41.2%)      | 27 (39.7%)           |        |
| B               | 20 (58.8%)      | 41 (60.3%)           |        |

Abbreviations: ER, enhanced recovery after surgery; BMI, Body mass index; WBC, white blood cells; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ASA, American Society of Anesthesiologists score.

The continuous variable data were expressed as mean ± standard deviation.
TABLE 2 Protocols of the ERAS program and traditional care for patients receiving LPD. All items involved in the protocols were listed in the table including preoperative, intraoperative and post-operative 1-4 days.

| POD 1 | ER group | Non-ER group |
|-------|----------|--------------|
| Preoperative | Counseling about fast-track rehabilitation programme while admission. | Traditional informed consent. |
| | Intake of clear fluids up to 3 h before anesthesia and normal oral nutrition until 6 h before surgery. | Overnight fasting. |
| | No bowel preparation before surgery | Oral bowel preparation. |
| Intraoperative | Restrictive intravenous fluids | Restrictive intravenous fluids |
| | Perioperative antibiotic Somatostatin | Perioperative antibiotic Somatostatin |
| | Acid suppression | Acid suppression |
| | Analgesia infusion pump | Analgesia infusion pump |
| | Postoperative vomiting prophylaxis with 5-HT receptor antagonist | |
| | Mobilization out of bed for >1 h or at least 3 times | |
| | Physiotherapy | |
| POD 2 | Oral elemental diet | Removal of urinary catheter after intermittent clamping |
| | Enhanced mobilization out of bed for >2 h or at least 6 times | Removal of nasogastric tube after flatus |
| POD 3 | Oral semisolid diet | Oral intake of elemental diet depending on patient’s progress including flatus |
| | Stop antibiotics | Removal of urinary catheter after intermittent clipping |
| | Removal of intra-abdominal drains if drain amylase less than 3-fold serum of 50 ml/d production | Bedside sitting and standing according to patient’s ability |
| | Enhanced mobilization out of bed for >4 h | |
| POD 4 | Gradual transfer to regular diet | Oral liquids |
| | All medication stopped except oral proton pump inhibitors and multivitamin | Stop antibiotics according to the inflammatory index |
| | Normal body temperature Ability to take solid foods without vomiting even only 1–2 times/day Adequate mobilization | Removal of intra-abdominal drains if drain amylase less than 3-fold serum and 50 ml/d production Untargeted mobilization |
| Discharge criteria | Normal body temperature Regular diet like the time before illness Adequate mobilization No abdominal pain | |

(continued)

TABLE 2 Continued

| ER group | Non-ER group |
|----------|--------------|
| No abdominal pain or controlled abdominal pain by oral pain medications (Tramadol 50mg, no more than twice per day, $0.32/tablet) | No obvious abnormalities in laboratory test |

Abbreviations: ERAS, enhanced recovery after surgery; LPD, laparoscopic pancreaticoduodenectomy; 5-HT, 5-hydroxytryptamine; POD post-operation day.

ERAS protocols

ERAS protocols were designed based on previously published ERAS guidelines (1), and we further refined and established our own standardized programmes (Table 2). Early oral intake and ambulation, active pain control, avoidance of unnecessary indwelling medical tubes, and promotion of patient autonomy were encouraged if the condition of the patients allowed. After surgery, patients went to the observation unit and then moved back to the ward. If vital signs were unstable, the patients went to ICU postoperatively. On postoperative day (POD) 1, anti-thrombotic prophylaxis, especially VTE prophylaxis and post VTE prophylaxis were performed. From POD 1, the patients began ambulation such as mobilization out of bed for >1 h or at least 3 times. If necessary, ambulation assist equipment could be used. Appropriate glucose loading was used on the day of surgery based on the energy need of the patients. Postoperative oral intake of liquids was started on POD 1–2, and elemental diet was started on POD 2, and solids were started on POD 3–4. Intake of rice porridge was started on POD 3 in parallel with elemental diet. Postoperative fluid management was adjusted based on oral intake. The intravenous fluid infusion volume was controlled within 1000–1500 ml. Nasogastric tubes were removed on POD 1 if nasogastric output was <300 ml/day. The urinary catheter was also removed on POD 1. Intra-abdominal drains were removed on POD 3 if amylase was less than 3-fold higher than the serum level and output was <50 ml/d. Physiotherapy was started on POD 1 and continued until discharge. For postoperative prophylaxis, piperacillin/tazobactam sodium was administered intravenously on the operative day (4.5 g, three times). The compliance with ERAS and non-ERAS core elements of each patient was recorded as either 0 for non-accomplished or 1 for accomplished.

Surgical procedures

The standard surgical procedures were performed in all patients, including gastrointestinal anastomosis and the
pancreateicojejunostomy (anastomosis of pancreatic duct mucosa and jejunum mucosa). The intra-abdominal drains were routinely placed at the site of the bilioenteric anastomosis and pancreateicojejunostomy.

**Statistical analysis**

SPSS 24.0 statistical software was used to analyse the data. The continuous variable data are shown as the mean ± standard deviation. Continuous variables were compared using Student’s t-tests with a normal distribution or nonparametric Mann–Whitney U-tests with an irregular distribution. Count data were analysed using χ² test, Fisher’s exact test and the rank sum test. A P value <0.05 was considered statistically significant.

**Results**

**Patient characteristics**

Clinical characteristics between two groups were compared using the following risk factors: gender, age, body mass index (BMI), American Association of Anaesthesiologists (ASA) score, and Child-Pugh score as well as measurements of white blood cells (WBC), neutrophils, haemoglobin, albumin, total bilirubin (TB), direct bilirubin (DB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) (Table 1). This study included 58 men (56.9%) and 44 women (43.1%) with an average age of 60.5 ± 9.2 years. The two groups were similar in terms of demographics and surgical characteristics (all P > 0.05). There was no difference in mean age, BMI, ASA score and Child-Pugh score between the ER and non-ER groups (both P > 0.05). Common laboratory tests, including WBC, TR, DB, AST, ALT and albumin, did not differ significantly between the two groups (P > 0.05).

**Operative outcomes**

There were no statistically significant differences were observed between the ER and non-ER groups in duration of surgery, intraoperative blood loss and transfusion, which are presented in Table 3. In the ER group, the mean duration of surgery was 462.7 (300–720) min, the operative blood loss was 523.5 (250–1200) ml, and 8.8% of patients received an intraoperative transfusion. However, in the non-ER group, the mean duration of surgery, operative blood loss and proportion of patients who received an intraoperative transfusion were 450.9 (300–760) min (P = 0.627), 537.5 (250–1500) ml (P = 0.800) and 11.8% (P = 0.746), respectively. The intravenous fluid infusion rate was 4.0 ml/kg/h. Usually, the ratio of crystalloid to colloid was from 2:1 to 3:1. The ER group had significantly lower total fluid and crystalloid volume than non-ER group (P < 0.01). There was no significant difference in the colloid volume between two groups. All patients used analgesic infusion pump in both groups.

**Post-operative outcomes**

Post-operative pathologic diagnosis found 3 and 6 benign lesions in ER group and non-ER group, respectively (P = 0.598). Others were tumors including pancreatic cancer, cholangiocarcinoma and duodenal adenocarcinoma (P > 0.05). Compared with non-ER groups, patients with ERAS spent shorter time in nasogastric tube remove, urinary catheter remove, intra-abdominal drains remove, first bowel gas time, first diet time, off-bed activity time, postoperative stay and total medical cost.

**TABLE 3** Demographics and perioperative variables in patients. 17 perioperative variables were used to compare between two groups including duration of surgery, intraoperative blood loss, patients transfused, intraoperative biliary drains, pathologic diagnosis, pancreatic cancer, cholangiocarcinoma, duodenal adenocarcinoma, benign lesion, nasogastric tube removal time urinary catheter removal time, intra-abdominal drains removal time, first bowel gas time, first diet time, off-bed activity time, postoperative stay and total medical cost.

| Variables                                | ER group (n = 34) | Non-ER group (n = 68) | P value |
|------------------------------------------|-------------------|-----------------------|---------|
| Duration of surgery (min)                | 462.7 ± 117.0     | 450.9 ± 109.8         | 0.627   |
| Intraoperative blood loss (ml)           | 523.5 ± 270.0     | 537.5 ± 241.8         | 0.800   |
| Patients transfused (year)               | 3 (8.8%)          | 8 (11.8%)             | 0.746   |
| Intraoperative biliary drains (year)     | 29 (85.3%)        | 48 (70.6%)            | 0.143   |
| Pathologic diagnosis                     |                   |                       |         |
| Pancreatic cancer                        | 18 (52.9%)        | 43 (63.2%)            | 0.393   |
| Cholangiocarcinoma                       | 8 (23.5%)         | 12 (17.6%)            | 0.598   |
| Duodenal adenocarcinoma                  | 5 (14.7%)         | 7 (10.3%)             | 0.528   |
| Benign lesion                            | 3 (8.8%)          | 6 (8.8%)              | 1.000   |
| Nasogastric tube removal time (days)     | 1.8 ± 0.9         | 3.6 ± 1.1             | <0.001  |
| Urinary catheter removal time (days)     | 2.1 ± 1.0         | 3.8 ± 1.1             | <0.001  |
| Intra-abdominal drains removal time (days)| 4.2 ± 1.2        | 7.2 ± 2.6             | <0.001  |
| First bowel gas time (days)              | 2.7 ± 0.9         | 4.0 ± 0.9             | <0.001  |
| First diet time (days)                   | 2.0 ± 0.6         | 3.5 ± 0.7             | <0.001  |
| Off-bed activity time (days)             | 2.3 ± 0.7         | 4.2 ± 0.9             | <0.001  |
| Postoperative stay (days)                | 15.8 ± 3.4        | 23.1 ± 5.1            | <0.001  |
| Total medical cost (¥10⁵)                | 14.3 ± 2.8        | 15.8 ± 2.9            | 0.017   |

Abbreviations: ER, enhanced recovery after surgery. The continuous variable data were expressed as mean ± standard deviation.
Postoperative complications

The complications included pancreatic or biliary fistula, haemorrhage, abdominal or pulmonary infection, unplanned reoperation, mortality rate and readmission within 30 days of the operation (Table 4). The overall complication rate was 32.4% (11 of 34 patients) in the ER group compared with 35.3% (24 of 68) in the non-ER group (P = 0.281). According to the clinical effect, postoperative pancreatic fistula has three grades (grade A, B and C) based primarily on the International Study Group on Pancreatic Fistula (ISGPF) (11). There were 7 and 14 patients with a grade A pancreatic fistula happened in the ER group and non-ER group, respectively, 3 and 5 patients in the ER group and non-ER groups developed a grade B pancreatic fistula after surgery, respectively. These patients were healed after treatment with abdominal puncture and B-ultrasound guided-drainage. There was no significant difference in the pancreatic fistula ratio between the two groups (P = 0.903). There was one patient with biliary fistula, delayed gastric emptying and pleural effusions or ascites in each group (P = 0.615), respectively. One patient with postoperative haemorrhage in non-ER group underwent a second surgery. Two patients with postoperative haemorrhage in ER group received blood transfusion and hemostasis treatments other than surgery (P = 0.216). In ER group, there was no patient with abdominal, pulmonary or wound infection, thrombosis, unplanned reoperation and dead. Correspondingly in patients with non-ER, there was one patient producing abdominal, or wound infection, thrombosis and unplanned reoperation, respectively (P = 0.480). One patient was dead (P = 0.480), and three patients underwent pulmonary infection (P = 0.216). Except one unplanned reoperation, the other postoperative complications were treated conservatively. One patient with ER chose readmission in 30 days due to ascites. According to the Clavien–Dindo grade (10), there was no significant difference in grade ≥ 3 complications between ER group and non-ER group (2 vs. 5 patients; P = 0.783). There was no difference in postoperative complications between the patients after LPD performed by Dr. Li and Dr. Yan. The median duration of postoperative fluid management was 9.5 days (range: 7.5–14 days) in the ER group and 14 days (range: 12.5–22 days) in the non-ER group (P < 0.01).

Cost analysis

The mean total medical costs per patient were $2.1 ± 0.7 × 10^4 and $2.3 ± 0.7 × 10^4 in ER group were lower than those in non-ER group. in the ER and non-ER groups, respectively (P = 0.017). Postoperative mean costs per patient were $2.0 × 10^4 in the ER group and $2.2 × 10^4 in the non-ER group (P = 0.019). ERAS was significantly associated with lower costs for medication, housing, nursing care and disposable material costs (P < 0.05) in the ER group compared with the non-ER group. The surgical and anesthetic costs were similar in the two groups (P > 0.05). In the enhanced recovery group, these patients had some extra radiological examinations or laboratory examinations to prevent accidental complications due to the enhanced recovery. Other laboratory and radiologic examination costs had no significant difference (P > 0.05).

Compliance with ERAS core elements

The recovery indicators for patients with ERAS or non-ER were comparatively analysed. The retention time of nasogastric tubes, urinary catheters and intra-abdominal drains in the ER group were significantly shorter than that in the non-ER group (P < 0.001). In addition, oral elemental diet and targeted mobilization after surgery in the ER group also occurred much earlier than that in the non-ER group.

### TABLE 4 Surgical complications

| Types | ER group (n = 34) | Non-ER group (n = 68) | P value |
|-------|------------------|-----------------------|---------|
| Pancreatic fistula, n (%) | 7 (20.6%) | 14 (20.6%) | 0.903 |
| Grade A | 3 (8.8%) | 5 (7.4%) | |
| Biliary fistula, n (%) | 1 (2.9%) | 1 (1.5%) | 0.615 |
| Postoperative hemorrhage, n (%) | 2 (5.9%) | 1 (1.5%) | 0.216 |
| Abdominal infection, n (%) | 0 (0%) | 1 (1.5%) | 0.480 |
| Pulmonary infection, n (%) | 0 (0%) | 3 (4.4%) | 0.216 |
| Wound infection, n (%) | 0 (0%) | 1 (1.5%) | 0.480 |
| Delayed gastric emptying, n (%) | 1 (2.9%) | 1 (1.5%) | 0.615 |
| Pleural effusions or ascites, n (%) | 1 (2.9%) | 1 (1.5%) | 0.615 |
| Thrombosis, n (%) | 0 (0%) | 1 (1.5%) | 0.480 |
| Unplanned reoperation | 0 (0%) | 1 (1.5%) | 0.480 |
| Mortality | 0 (0%) | 1 (1.5%) | 0.480 |
| Readmission in 30 days, n (%) | 1 (2.9%) | 0 (0%) | 0.157 |

Clavien–Dindo grades

- No: 23 (67.6%) | 44 (64.7%)
- 1–2: 9 (26.5%) | 19 (14.7%)
- 3a: 1 (2.9%) | 1 (1.5%)
- 3b: 0 (0%) | 1 (1.5%)
- 4a: 1 (2.9%) | 1 (1.5%)
- 4b: 0 (0%) | 1 (1.5%)
- 5: 0 (0%) | 1 (1.5%)
- Grad ≥3: 2 (18.2%) | 5 (20.8%) | 0.782
In addition, there were several patients deviating from the ERAS protocols. The nasogastric tube was removed on POD 1 in 26 (76.5%) patients, but four patients (11.8%) could not start oral intake of an elemental diet on POD 2. The overall compliance rates to protocol were 89.2% in ER group and 57.4.8% in non-ER group (P < 0.01), respectively. As shown in Table 5, early removal of urinary catheter and intra-abdominal drains were more difficult to follow in both groups. Compare with ER group, it was not easy to perform vomiting prophylaxis, early removal of nasogastric tube and early oral elemental diet in patients with non-ER (P < 0.001).

**Discussion**

To the best of our knowledge, this is the first clinical observational study in China to investigate the feasibility and safety of ERAS protocols in patients after LPD. The present study suggests that ERAS programmes may have benefits in facilitating earlier patient recovery, which included earlier first bowel gas time, first diet time, and off-bed activity time; shorter drainage tube retention time; shorter postoperative stay; and lower medical costs. Meanwhile, there was no significant difference in most postoperative complication rates and 30-day readmissions between the two treatments.

Compared to OPD, LPD is a less invasive surgical procedure with higher risk that requires advanced laparoscopic skills for senior surgeons. The incidence of postoperative complications of LPD is still as high as 30%–50%, even when performed by an expert surgeon. Thus, it seems that ERAS programmes for LPD might not be widely accepted. In fact, implementation of ERAS is now expanding across a wide range of complex laparoscopic surgical procedures and specialties, such as colorectal resection (12), liver resection (13), and gynecologic oncology (14), and the benefits of ERAS have been well proven in these surgeries. For the first time, our observational results demonstrated the safety and efficiency of implementing ERAS protocols for LPD. However, RCTs are required to provide further evidence about ERAS protocols for LPD.

In this study, the postoperative stay was decreased significantly in ER group. This may be clinically important because early oral elemental diet and targeted mobilization lead to fast recovery and increased immunity of patients after surgery, and subsequently reducing the length of hospital stay. In the ER group, earlier first diet and off-bed activity after surgery were encouraged for patients following LPD, which may have resulted in earlier bowel gas. Currently, increasing studies have shown that long-term fasting may lead to slower recovery of intestinal peristalsis (15) and increased risk of metabolic disorders (16), which is not conducive to patient recovery. Early enteral feeding can reduce postoperative infections and shorten postoperative hospital stays (17). Feeding proximally to the anastomosis does not increase the risk of bowel anastomosis (18). Balzano et al. showed that early feeding did not increase the incidence of pancreatic fistula after surgery but could reduce the incidence of gastric emptying (19). Considering the complexity of LPD, in our protocols, the patients turned over or moved their limbs on the bed on POD 1, then moved legs on the bedside, and finally got out of bed for small-scale exercise. We thought that the premise for early ambulation was effective analgesia and early removal of various drainage tubes.

The shorter retention time of urinary catheters, nasogastric tubes and intra-abdominal drains could reduce some related postoperative complications. Indwelling urinary catheters can increase the risk of postoperative lung and urinary tract infections (20), and indwelling nasogastric tubes contribute to a high risk of lung infection in patients (21), which further delays patient recovery. Moreover, a multicentre RCT showed that the absence of an intra-abdominal drain after OPD significantly increased the incidence of complications and mortality by 4 fold (22). Therefore, this practice is reasonable to implement in patients with intra-abdominal drains following LPD. However, this study also suggests that early
Our data suggest the efficiency of ERAS programmes for decreasing postoperative complications and morbidity, which is consistent with a previous RCT on ERAS protocols for OPD (7). Moreover, a recent retrospective study found that lower pre-albumin level, higher ASA score and longer operative time were independent risk factors for failure of early recovery from OPD and increased complications of ERAS for OPD (5). Of note, we found that more patients had pulmonary infections in the non-ER group compared with the ER group. This result may be associated with the early ambulation of ERAS protocols, which could promote expectoration and immunity of patients and decrease the opportunity for pulmonary infection.

ERAS pathways showed reduced medical costs with LPD. Compared to non-ER, surgical and anaesthetic costs were not different, but the costs of wards and beds, laboratory and radiologic examinations, and medications were decreased significantly, which resulted in lower total medical cost. Other reasons for reduced medical costs may be attributed to the shorter postoperative hospitalization time and less postoperative complications, with no increase in the readmission rate. Consequently, the patients could benefit from the reduced healthcare costs of LPD via ERAS programs.

Another important finding was that ERAS programmes did not increase the risk of postoperative haemorrhage and biliary or pancreatic fistula. Given the technically challenging nature of the LPD procedure, it requires higher laparoscopic skill with regard to accurate needle handling to prevent suture tangling in the biliary/pancreatic ducts and intestinal/pancreatic tissues. In our study, the two surgeons were experienced laparoscopic surgical experts and completed the initial learning curve, which could help to avoid technical bias. Moreover, we do not support the recommendation for routine preoperative endoscopic nasal biliary drainage for patients undergoing LPD.

The main limitations of our study are the nature of the retrospective study and the small sample in a single medical centre. We have not compared the surgical effects between LPD and OPD during the same period. To date, there is no widely accepted guideline or recommendation for ERAS programmes for LPD. Therefore, all the basic components of the “fast-track” or ERAS programmes for LPD in our study are based on other protocols for OPD in other different laparoscopic surgical specialties. Some factors would produce some differences in the implementation of ERAS between LPD and OPD, such as the influences of surgical wound size, carbon dioxide pneumoperitoneum pressure, patient psychology status induced by different surgical methods and diet time. However, according to our results, the majority of OPD protocols could be implemented in the ERAS of LPD. A different selection of LPD patient population mainly comes from the requirements of laparoscopic surgery. Moreover, our results need to be validated by additional future studies or stratified analysis. Furthermore, compared to the west countries, the mean length of postoperative hospital stay was still longer in both groups. The difference may come from the eastern traditional culture of health care requiring long-term postoperative recuperation. On the other hand, Chinese medical insurance policy does not strictly control the length of the hospital stay and many Chinese patients did not strictly follow the doctor’s discharge schedule. We believe it could be further shortened if Chinese patients are more able to follow the surgeons’ guidance. In addition, the introduction of laparoscopic procedure perhaps led to clinicians challenging their traditional viewpoints of postoperative care which has been aided by the ERAS groups research. Therefore, a more evidence based postoperative care program should be introduced in the future.

In summary, ERAS protocols for LPD can effectively reduce the length of postoperative stay and medical costs and do not increase the incidence of postoperative complications. However, individualized ERAS measures for LPD should be formulated in light of clinical practice and previous studies. In future studies, more intensive multimodal approaches should be optimized and improved to maximize patient benefit.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Ethics statement

This study protocol has been reviewed and approved by the Ethics Review Board of the First Affiliated Hospital of Chongqing Medical University. All patients and/or their legal guardians were required to provide informed consent to participate in this study.

Author contributions

RL: Data curation, Formal analysis, Funding acquisition, Writing–original draft; J-CL: Data curation, Formal analysis, Methodology, Writing – review; JC and X-FW: Formal analysis, Methodology, Writing – review; XY: Conceptualization, Supervision, Writing – review & editing. All authors contributed to the article and approved the submitted version.
Funding

This manuscript was funded by the Science and Health Joint Research Project of Chongqing Municipality (2020GDRC013 and 2021MSXM056).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Lassen K, Coolsen MM, Slim K, Carli F, de Aguilar-Nanciamento JE, Schafer M, et al. Guidelines for perioperative care for pancreaticoduodenectomy: enhanced recovery after surgery (ERAS(R)) society recommendations. Clin Nutr. (2012) 31(6):817–30. doi: 10.1016/j.clnu.2012.08.011

2. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. (2017) 152(3):292–8. doi: 10.1001/jamasurg.2016.4952

3. Schram A, Ferreira V, Minzelfa EM, Awashti R, Carli F, Scheede-Bergdahl C. In-hospital resistance training to encourage early mobilization for enhanced recovery programs after colorectal cancer surgery: a feasibility study. Eur J Surg Oncol. (2019) 45:1592–7. doi: 10.1016/j.ejso.2019.04.015

4. Engellin DT, Ben Ali W, Williams JR, Perrault LP, Reddy VS, Arora RC, et al. Guidelines for perioperative care in cardiac surgery: enhanced recovery after surgery society recommendations. JAMA Surg. (2019) 154(8):755–66. doi: 10.1001/jamasurg.2019.1153

5. Kobayashi S, Segami K, Hoshino H, Nakahara K, Katayama M, Kozumi S, et al. Risk factors for failure of early recovery from pancreaticoduodenectomy despite the use of enhanced after surgery protocols and a physical aging score to predict postoperative risks. J Hepatobiliary Pancreat Sci. (2018) 25(4):231–9. doi: 10.1002/jhbp.540

6. Mahvi DA, Pak LM, Bose SK, Urman RD, Gold JS, Whang EE, et al. Fast-Track pancreatectoduodenectomy: factors associated with early discharge. World J Surg. (2019) 43(5):1332–41. doi: 10.1007/s00268-019-04916-0

7. Takagi K, Yoshida R, Yagi T, Umeda Y, Nohouka D, Kusie T, et al. Effect of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy: a randomized controlled trial. Clin Nutr. (2019) 38 (1):174–81. doi: 10.1016/j.clnu.2018.01.002

8. Ji HB, Zhu WT, Wei Q, Wang XX, Wang HB, Chen QP. Impact of enhanced recovery after surgery programs on pancreatic surgery: a meta-analysis. World J Gastroenterol. (2018) 24(15):1666–78. doi: 10.3748/wjg.v24.i15.1666

9. Ding J, Zhang C, Huang D, Zhang Y. The state of minimally invasive pancreaticoduodenectomy in Chinese mainland: a systematic literature review. Biosci Trends. (2020) 13(6):488–501. doi: 10.5582/bst.2019.01278

10. Bassi C, Marchegiani G, Giuliani T, Di Gioia A, Andrianello S, Zingaretti CC, et al. Pancreaticoduodenectomy at the verona pancreas institute: the evolution of indications, surgical techniques and outcomes: a retrospective analysis of 3000 consecutive cases. Ann Surg. (2021). doi: 10.1097/SLA.0000000000004753. [Epub ahead of print]

11. Bassi C, Dervenis C, Butturrini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. (2005) 138:8–13. doi: 10.1016/surg.2005.03.001

12. Hüscher CG, Bretagno F, Corcione F. Laparoscopic colorectal cancer resection in high-volume surgical centers: long-term outcomes from the LAPCOLON group trial. World J Surg. (2015) 39(8):2045–51. doi: 10.1007/j00268-015-3050-4

13. Liang X, Ying H, Wang H, Xu H, Liu M, Zhou H, et al. Enhanced recovery care versus traditional care after laparoscopic liver resections: a randomized controlled trial. Surg Endosc. (2018) 32(6):2746–57. doi: 10.1007/s00464-017-5973-3

14. Plett H, Ricciardi E, Bommert M, Veldink H, Traut A, Pietzner K, et al. Current practice and physicians’ opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology-oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany. Arch Gynecol Obstet. (2019) 299(6):1607–18. doi: 10.1007/s00404-019-05132-w

15. Mari GM, Costanzo A, Maggioni D, Origi M, Ferrari GC, De Martini P, et al. Fast-track versus standard care in laparoscopic high anterior resection: a prospective randomized-controlled trial. Surg Laparosc Endosc Percutan Tech. (2014) 24(2):118–21. doi: 10.1097/SLE.0b013e3182a503e3

16. Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and clinical outcomes of metabolic (disfunction)-associated fatty liver disease. J Clin Transl Hepatol. (2021) 9(6):972–82. doi: 10.14218/JCTH.2021.00201

17. Zhu XH, Wu YF, Qiu YD, Jiang CP, Ding YT. Effect of early enteral combined with parenteral nutrition in patients undergoing pancreaticoduodenectomy. World J Gastroenterol. (2013) 19(35):5889–96. doi: 10.3748/wjg.v19.i35.5889

18. Yin J, Chen Z, Niu W, Feng L, Fan B, Zhou L, et al. Using a multidisciplinary team for the staged management and optimally minimally invasive treatment of severe acute pancreatitis. Biosci Trends. (2015) 9(3):180–7. doi: 10.5582/bst. 2015.01075

19. Balzano G, Zerbi A, Braga M, Rocchetti S, Beneduce AA, Di Carlo V. Fast-track recovery programme after pancreatico-duodenectomy reduces delayed gastric emptying. Br J Surg. (2008) 95:1387–93. doi: 10.1002/bjs.6324

20. Ma Y, Lu X. Indwelling catheter can increase postoperative urinary tract infection and may not be required in total joint arthroplasty: a meta-analysis of randomized controlled trial. BMC Musculoskelet Disord. (2019) 20(1):11. doi: 10.1186/s12891-018-2395-x

21. Lingiah VA, Pyrsopoulos NT. Bacterial infections in cirrhotic patients in a tertiary care hospital. J Clin Transl Hepatol. (2021) 9(1):32–9. doi: 10.14218/JCTH.2020.00076

22. Van Buren 2nd G, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, et al. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg (2014) 259(4):605–12. doi: 10.1097/SLA.0000000000000460